Re­searchers de­fine ex­act­ly what they saw in the first pos­i­tive remde­sivir study for Covid-19. But what's that worth to Gilead?

Remde­sivir can work in fight­ing Covid-19, par­tic­u­lar­ly for pa­tients with less se­vere cas­es, but this is just a first step in the jour­ney to find­ing com­bos that can do the job much bet­ter.

That’s the bot­tom line from Gilead’s ran­dom­ized study pub­lished in the New Eng­land Jour­nal of Med­i­cine. An­a­lysts were quick to draw con­clu­sions about how the big biotech could turn this in­to a prof­itable ad­van­tage — with wide­spread ex­pec­ta­tion of con­sid­er­able pric­ing re­straint on Gilead’s part. Any­one look­ing for a new moun­tain of cash to count as the world grap­ples with the pan­dem­ic is like­ly to come away dis­ap­point­ed.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.